SKB575-I-02: A Randomized, Phase Ib, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SKB575 (HBM7575) in Participants With Asthma (clinicaltrials.gov) - Sep 11, 2026 - P1 | N=36 | Recruiting | Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases
|